Metabolic Reprogramming in MDA-MB-468 Cells

Metabolic reprogramming is a hallmark of cancer cells, allowing them to adapt to the high energy demands required for proliferation and survival. In our recent study, we investigated the unique metabolic profile of MDA-MB-468 cells, a triple-negative breast cancer (TNBC) cell line that exhibits significant alterations in glucose metabolism, glutamine utilization, and lipid synthesis pathways compared to normal breast epithelial cells.

Elevated Glycolytic Activity: The Warburg Effect in MDA-MB-468 Cells

Our analysis of MDA-MB-468 cells revealed a significant upregulation of glycolytic activity regardless of oxygen availability, a phenomenon known as the Warburg effect. Using extracellular flux analysis, we observed that these triple-negative breast cancer cells exhibit a 3.2-fold higher glucose consumption rate and a 2.7-fold increase in lactate production compared to MCF-10A normal breast epithelial cells. This metabolic shift was accompanied by enhanced expression of key glycolytic enzymes, including hexokinase II (HK-II), phosphofructokinase (PFK), and lactate dehydrogenase A (LDHA).

Glutamine Dependency: A Critical Metabolic Vulnerability

Beyond glycolytic alterations, our research uncovered pronounced glutamine addiction in MDA-MB-468 cells. Metabolic tracing experiments using 13C-glutamine demonstrated that these cells direct glutamine-derived carbon predominantly toward TCA cycle intermediates and nucleotide synthesis, with glutaminase (GLS) expression elevated 4.5-fold compared to control cells. When subjected to glutamine deprivation or GLS inhibition using CB-839, MDA-MB-468 cells showed dramatic reductions in proliferation (78% decrease) and viability (65% decrease), while normal breast epithelial cells remained largely unaffected. This distinct metabolic dependency offers a promising therapeutic window for targeted interventions.

Enhanced Lipid Metabolism: Accelerated Fatty Acid Synthesis

Investigation of the lipid metabolic landscape in MDA-MB-468 cells revealed substantial rewiring of fatty acid synthesis pathways. Using mass spectrometry-based lipidomics, we identified a 2.8-fold increase in de novo lipogenesis compared to non-malignant controls. This was correlated with elevated expression of fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and sterol regulatory element-binding protein 1 (SREBP1). Inhibition of FASN with TVB-2640 resulted in significant accumulation of malonyl-CoA and triggered apoptosis specifically in MDA-MB-468 cells. Additionally, these cells showed reduced β-oxidation capacity, suggesting a preferential shift toward lipid synthesis rather than utilization for energy production.

Targeted Metabolic Inhibition: Promising Therapeutic Approaches

Our investigation into metabolic inhibitors targeting the altered pathways in MDA-MB-468 cells yielded encouraging anti-cancer effects. Treatment with 2-deoxy-D-glucose (2-DG) to inhibit glycolysis reduced cell viability by 62% at 10 mM concentration, while CB-839-mediated glutaminase inhibition was effective at nanomolar concentrations (IC50 = 35 nM). FASN inhibition with TVB-2640 demonstrated significant growth suppression (58% reduction at 200 nM) and induced apoptosis markers including cleaved caspase-3 and PARP. Importantly, normal breast epithelial MCF-10A cells showed minimal sensitivity to these treatments when administered at concentrations effective against MDA-MB-468 cells, highlighting the potential therapeutic window for metabolism-targeting approaches.

Synergistic Effects of Combination Metabolic Therapy

Exploiting the multiple metabolic vulnerabilities of MDA-MB-468 cells, we evaluated combination therapies targeting different metabolic pathways simultaneously. The dual inhibition of glycolysis and glutamine metabolism (2-DG + CB-839) produced a strong synergistic effect (combination index = 0.47), resulting in 92% growth inhibition at concentrations that were only modestly effective as monotherapies. Similarly, combining FASN inhibitor TVB-2640 with CB-839 demonstrated remarkable synergy (combination index = 0.39), triggering extensive apoptosis and cell cycle arrest. Mechanistically, this heightened efficacy appeared to stem from the cells' inability to compensate for multi-pathway metabolic disruption, as evidenced by comprehensive metabolomic analysis. These findings suggest that targeting the metabolic plasticity of MDA-MB-468 cells through rational combination therapies may provide a more effective treatment strategy than single-pathway interventions.